Search for: "Wyeth Pharmaceuticals"
Results 21 - 40
of 978
Sort by Relevance
|
Sort by Date
8 Apr 2019, 9:35 am
TTi serves a diverse clientele, including all stakeholders in the health space (governments, payors, providers, pharmaceutical and device companies, and foundations) who have a vested interest in advancing research to improve patient outcomes, population health, and access to care while reducing costs and eliminating health disparities. [read post]
27 Mar 2019, 1:00 am
Pharmaceutical Pricing Jaime King, University of California Hastings College of the Law, The Burden of Federalism: Challenges to State Attempts at Controlling Prescription Drug Costs Marc Rodwin, Suffolk University Law School, Controlling Pharmaceutical Prices: What the U.S. [read post]
2 Jan 2019, 7:07 am
This regulatory process for manufacturers to alter their warning labels plays a central role in pharmaceutical pre-emption after Wyeth. [read post]
1 Nov 2018, 8:00 am
Supreme Court’s decision in Wyeth v. [read post]
31 Jul 2018, 2:29 pm
Martoma’s portfolio included two pharmaceutical companies, Elan Corporation, plc (“Elan”) and Wyeth Pharmaceuticals, Inc. [read post]
31 Jul 2018, 2:29 pm
Martoma’s portfolio included two pharmaceutical companies, Elan Corporation, plc (“Elan”) and Wyeth Pharmaceuticals, Inc. [read post]
20 Mar 2018, 8:00 am
Supreme Court in Wyeth v. [read post]
17 Jan 2018, 1:16 pm
Wyeth, Inc. (9th Cir. 2014) 579 Fed. [read post]
14 Jan 2018, 6:34 am
(Wyeth, 555 U.S. at p. 578; see id. at p. 579 [“State tort suits uncover unknown drug hazards and provide incentives for drug manufacturers to disclose safety risks promptly. [read post]
13 Jan 2018, 8:00 pm
Wyeth, Inc. [read post]
18 Sep 2017, 11:12 am
Its ruling is the latest in a series of plaintiff-friendly decisions that misconstrued the Supreme Court’s landmark 2009 ruling in Wyeth Inc. v. [read post]
27 Aug 2017, 10:01 pm
Pay-for-delay Listen up, direct purchasers of pharmaceuticals. [read post]
27 Aug 2017, 10:01 pm
Pay-for-delay Listen up, direct purchasers of pharmaceuticals. [read post]
30 Aug 2016, 2:33 pm
Wyeth, Inc., Dr. [read post]
16 Aug 2016, 5:15 pm
Apotex tried IPR to invalidate a Wyeth patent.In March 2013, Apotex filed a petition to institute interpartes review of the ’828 patent [of Wyeth]. [read post]
16 Aug 2016, 10:52 am
Wyeth LLC, App. [read post]
28 Jun 2016, 9:02 am
Mensing limited generic drug makers’ pharmaceutical injury liability. [read post]
26 Jun 2016, 3:31 am
Wyeth, in which a California appeals court determined the brand name maker of a drug called Reglan, used to treat gastroesophageal reflux disease, could be found liable for injury caused by the generic version. [read post]
20 May 2016, 4:05 am
Wyeth, Inc., 872 F. [read post]
6 May 2016, 12:30 pm
Tap Pharmaceuticals, Inc., 2004 WL 2550593, at *5 (W.D. [read post]
